RxDoctor Payments Data

Robert Thayer, DO

Internal Medicine · Los Angeles, CANPI 1396199378

Payments from drug & device makers

$845in general payments, 2019–2025

Across 37 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$215
  • Pfizer$97
  • Bausch Health US, LLC$68
  • Novo Nordisk$67
  • Novartis$59
  • Shield Therapeutics Inc$52
  • plus $287 from 10 others

What the payments were for

  • Food & beverage$845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$845 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$74,216
Medicare patients
197
Services billed
3,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$98,609
EliquisApixaban60$76,428
FarxigaDapagliflozin Propanediol19$27,231
MounjaroTirzepatide13$18,353
JardianceEmpagliflozin17$16,768
LinzessLinaclotide16$14,725
Tresiba Flextouch U-200Insulin Degludec14$8,895
MyrbetriqMirabegron14$7,525
Tamsulosin Hcl178$2,947
Albuterol Sulfate HfaAlbuterol Sulfate76$2,565
Famotidine145$2,494
Atorvastatin Calcium199$2,287
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med33$2,281
Losartan Potassium134$1,745
Dutasteride40$1,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$67$98,60999 claims
PfizerEliquis$97$76,42860 claims
Lilly USA, LLCMounjaro$46$18,35313 claims
Boehringer IngelheimJardiance$23$16,76817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →